DETeCD-ADRD特刊介绍。
Introduction to the DETeCD-ADRD special issue.
作者信息
Dickerson Bradford C, Atri Alireza
机构信息
Frontotemporal Disorders Unit and Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Banner Sun Health Research Institute and Banner Alzheimer's Institute, Banner Health, Sun City, Arizona, USA.
出版信息
Alzheimers Dement. 2025 Feb;21(2):e14483. doi: 10.1002/alz.14483. Epub 2024 Dec 28.
Abstract
This special issue contains multiple articles related to the DETeCD-ADRD guideline.
摘要
本期特刊包含多篇与DETeCD - ADRD指南相关的文章。
相似文献
1
Introduction to the DETeCD-ADRD special issue.DETeCD-ADRD特刊介绍。
Alzheimers Dement. 2025 Feb;21(2):e14483. doi: 10.1002/alz.14483. Epub 2024 Dec 28.
2
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.阿尔茨海默病协会关于疑似阿尔茨海默病及相关疾病的诊断评估、检测、咨询与信息披露的临床实践指南（DETeCD - ADRD）：专科护理建议执行摘要
Alzheimers Dement. 2025 Jan;21(1):e14337. doi: 10.1002/alz.14337. Epub 2024 Dec 23.
3
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.阿尔茨海默病协会关于疑似阿尔茨海默病及相关疾病的诊断评估、检测、咨询与信息披露的临床实践指南（DETeCD - ADRD）：初级保健建议执行摘要
Alzheimers Dement. 2024 Dec 23. doi: 10.1002/alz.14333.
4
The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Validated clinical assessment instruments.阿尔茨海默病协会关于疑似阿尔茨海默病及相关疾病的诊断评估、检测、咨询和信息披露的临床实践指南（DETeCD - ADRD）：经过验证的临床评估工具。
Alzheimers Dement. 2025 Jan;21(1):e14335. doi: 10.1002/alz.14335. Epub 2024 Dec 23.
5
Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings.阿尔茨海默病协会关于在专科护理环境中对疑似阿尔茨海默病进行诊断检查时使用血液生物标志物的临床实践指南。
Alzheimers Dement. 2025 Jul;21(7):e70535. doi: 10.1002/alz.70535.
6
The role of neuropsychological assessment in the evaluation of patients with cognitive-behavioral change due to suspected Alzheimer's disease and other causes of cognitive impairment and dementia.神经心理学评估在疑似阿尔茨海默病及其他认知障碍和痴呆病因导致的认知行为改变患者评估中的作用。
Alzheimers Dement. 2025 Jan;21(1):e14363. doi: 10.1002/alz.14363. Epub 2024 Dec 28.
7
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍（MCI）患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
8
Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).用于检测轻度认知障碍（MCI）患者中阿尔茨海默病及其他痴呆症的简易精神状态检查表（MMSE）。
Cochrane Database Syst Rev. 2015 Mar 5;2015(3):CD010783. doi: 10.1002/14651858.CD010783.pub2.
9
The patient pathway for mild cognitive impairment due to Alzheimer's disease in Asia: Current practices, barriers, and expert recommendations for optimization.亚洲阿尔茨海默病所致轻度认知障碍的患者诊疗路径：当前实践、障碍及优化的专家建议
J Prev Alzheimers Dis. 2025 Aug;12(7):100215. doi: 10.1016/j.tjpad.2025.100215. Epub 2025 Jun 6.
10
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.马克 VCID 脑小血管联盟：一、入组、临床、液体方案。
Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21.
引用本文的文献
1
Early detection of Alzheimer's disease progression stages using hybrid of CNN and transformer encoder models.使用卷积神经网络（CNN）和变压器编码器模型的混合方法早期检测阿尔茨海默病进展阶段
Sci Rep. 2025 May 14;15(1):16799. doi: 10.1038/s41598-025-01072-5.
本文引用的文献
1
Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy.边缘叶为主的年龄相关性TDP-43脑病的临床标准。
Alzheimers Dement. 2025 Jan;21(1):e14202. doi: 10.1002/alz.14202. Epub 2025 Jan 14.
2
Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation.作为一种临床生物学概念的阿尔茨海默病——国际工作组建议
JAMA Neurol. 2024 Dec 1;81(12):1304-1311. doi: 10.1001/jamaneurol.2024.3770.
3
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.《痴呆症的预防、干预与照护：柳叶刀常设委员会2024年报告》
Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31.
4
A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer's disease.阿尔茨海默病诊断与分期修订标准的临床视角
Nat Aging. 2024 Aug;4(8):1029-1031. doi: 10.1038/s43587-024-00675-3.
5
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
6
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.基于生物标志物的神经认知障碍诊断的欧洲协会间推荐意见。
Lancet Neurol. 2024 Mar;23(3):302-312. doi: 10.1016/S1474-4422(23)00447-7.
7
Who gets to decide on what it means to have Alzheimer's disease?谁来决定患阿尔茨海默病意味着什么？
J Am Geriatr Soc. 2024 Jun;72(6):1939-1941. doi: 10.1111/jgs.18793. Epub 2024 Feb 12.
8
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria.帕金森病的生物学分类：SynNeurGe 研究诊断标准。
Lancet Neurol. 2024 Feb;23(2):191-204. doi: 10.1016/S1474-4422(23)00404-0.
9
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义：建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
10
Proposed research criteria for prodromal behavioural variant frontotemporal dementia.前驱期行为变异额颞叶痴呆的研究标准草案。
Brain. 2022 Apr 29;145(3):1079-1097. doi: 10.1093/brain/awab365.
Zotero 插件